ImmPort Study ID	PubMed	Study Title	PI	Biosample ID	Experiment ID	Cohort	Repository Accession	Type	Biosample Name	Biosample Description	Species	Strain	Cancer Type
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194309	GSE87424	EpCAM/CD49f negative SUM229 breast carcinoma subpopulation	GSM2330625	None	SUM229neg_30nMtrametinib_24h	None	Human	SUM229neg_30nMtrametinib_24h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194328	GSE87424	HCC1806 breast carcinoma cell line	GSM2330644	None	Figure3_HCC1806_300nMJQ1_48h	Figure3_HCC1806_normalizedRSEM.xlsx	Human	Figure3_HCC1806_300nMJQ1_48h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194329	GSE87424	HCC1806 breast carcinoma cell line	GSM2330645	None	Figure3_HCC1806_10nMtrametinib300nMJQ1_48h	Figure3_HCC1806_normalizedRSEM.xlsx	Human	Figure3_HCC1806_10nMtrametinib300nMJQ1_48h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194326	GSE87424	HCC1806 breast carcinoma cell line	GSM2330642	None	Figure3_HCC1806_DMSO_48h	Figure3_HCC1806_normalizedRSEM.xlsx	Human	Figure3_HCC1806_DMSO_48h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194327	GSE87424	HCC1806 breast carcinoma cell line	GSM2330643	None	Figure3_HCC1806_10nMtrametinib_48h	Figure3_HCC1806_normalizedRSEM.xlsx	Human	Figure3_HCC1806_10nMtrametinib_48h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194307	GSE87424	EpCAM/CD49f positive SUM229 breast carcinoma subpopulation	GSM2330623	None	SUM229pos_30nMtrametinib_24h	None	Human	SUM229pos_30nMtrametinib_24h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194308	GSE87424	EpCAM/CD49f negative SUM229 breast carcinoma subpopulation	GSM2330624	None	SUM229neg_DMSO_24h	None	Human	SUM229neg_DMSO_24h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194306	GSE87424	EpCAM/CD49f positive SUM229 breast carcinoma subpopulation	GSM2330622	None	SUM229pos_DMSO_24h	None	Human	SUM229pos_DMSO_24h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194314	GSE87424	SUM159 breast carcinoma cell line	GSM2330630	None	SUM159_DMSO_24h_replicate1	DESeq2_SUM159replicates.xlsx	Human	SUM159_DMSO_24h_replicate1	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194315	GSE87424	SUM159 breast carcinoma cell line	GSM2330631	None	SUM159_100nM_trametinib_24h_replicate1	DESeq2_SUM159replicates.xlsx	Human	SUM159_100nM_trametinib_24h_replicate1	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194316	GSE87424	SUM159 breast carcinoma cell line	GSM2330632	None	SUM159_300nMJQ1_24h_replicate1	None	Human	SUM159_300nMJQ1_24h_replicate1	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194317	GSE87424	SUM159 breast carcinoma cell line	GSM2330633	None	SUM159_100nMtrametinib300nMJQ1_24h_replicate1	None	Human	SUM159_100nMtrametinib300nMJQ1_24h_replicate1	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194318	GSE87424	SUM159 breast carcinoma cell line	GSM2330634	None	SUM159_DMSO_24h_replicate2	DESeq2_SUM159replicates.xlsx;SUM159_replicate2_normalizedRSEM.xlsx	Human	SUM159_DMSO_24h_replicate2	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194319	GSE87424	SUM159 breast carcinoma cell line	GSM2330635	None	SUM159_100nM_trametinib_24h_replicate2	DESeq2_SUM159replicates.xlsx;SUM159_replicate2_normalizedRSEM.xlsx	Human	SUM159_100nM_trametinib_24h_replicate2	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194320	GSE87424	SUM159 breast carcinoma cell line	GSM2330636	None	SUM159_300nMJQ1_24h_replicate2	SUM159_replicate2_normalizedRSEM.xlsx	Human	SUM159_300nMJQ1_24h_replicate2	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194321	GSE87424	SUM159 breast carcinoma cell line	GSM2330637	None	SUM159_100nMtrametinib300nMJQ1_24h_replicate2	SUM159_replicate2_normalizedRSEM.xlsx	Human	SUM159_100nMtrametinib300nMJQ1_24h_replicate2	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194322	GSE87424	SUM159 breast carcinoma cell line	GSM2330638	None	SUM159_DMSO_24h_replicate3	DESeq2_SUM159replicates.xlsx;SUM159_replicate3_normalizedRSEM.xlsx	Human	SUM159_DMSO_24h_replicate3	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194323	GSE87424	SUM159 breast carcinoma cell line	GSM2330639	None	SUM159_100nM_trametinib_24h_replicate3	DESeq2_SUM159replicates.xlsx;SUM159_replicate3_normalizedRSEM.xlsx	Human	SUM159_100nM_trametinib_24h_replicate3	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194324	GSE87424	SUM159 breast carcinoma cell line	GSM2330640	None	SUM159_300nMJQ1_24h_replicate3	SUM159_replicate3_normalizedRSEM.xlsx	Human	SUM159_300nMJQ1_24h_replicate3	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194325	GSE87424	SUM159 breast carcinoma cell line	GSM2330641	None	SUM159_100nMtrametinib300nMJQ1_24h_replicate3	SUM159_replicate3_normalizedRSEM.xlsx	Human	SUM159_100nMtrametinib300nMJQ1_24h_replicate3	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194330	GSE87424	SUM159 breast carcinoma cell line	GSM2330646	None	Figure7_SUM159_3uMSGCCBP30_24h	None	Human	Figure7_SUM159_3uMSGCCBP30_24h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194331	GSE87424	SUM159 breast carcinoma cell line	GSM2330647	None	Figure7_SUM159_100nMtrametinib3uMSGCCBP30_24h	None	Human	Figure7_SUM159_100nMtrametinib3uMSGCCBP30_24h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194332	GSE87424	SUM159 breast carcinoma cell line	GSM2330648	None	Figure7_SUM159_500nMIBET151_24h	None	Human	Figure7_SUM159_500nMIBET151_24h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194333	GSE87424	SUM159 breast carcinoma cell line	GSM2330649	None	Figure7_SUM159_100nMtrametinib500nMIBET151_24h	None	Human	Figure7_SUM159_100nMtrametinib500nMIBET151_24h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194334	GSE87424	SUM159 breast carcinoma cell line: xenograft	GSM2330650	None	SUM159xenograft_mouse1_2mpktrametinib_48h	None	Human	SUM159xenograft_mouse1_2mpktrametinib_48h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194335	GSE87424	SUM159 breast carcinoma cell line: xenograft	GSM2330651	None	SUM159xenograft_mouse2_2mpktrametinib_48h	None	Human	SUM159xenograft_mouse2_2mpktrametinib_48h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194336	GSE87424	SUM159 breast carcinoma cell line: xenograft	GSM2330652	None	SUM159xenograft_mouse3_2mpktrametinib_48h	None	Human	SUM159xenograft_mouse3_2mpktrametinib_48h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194337	GSE87424	SUM159 breast carcinoma cell line: xenograft	GSM2330653	None	SUM159xenograft_mouse1_2mpktrametinib30mpkIBET151_48h	None	Human	SUM159xenograft_mouse1_2mpktrametinib30mpkIBET151_48h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194338	GSE87424	SUM159 breast carcinoma cell line: xenograft	GSM2330654	None	SUM159xenograft_mouse2_2mpktrametinib30mpkIBET151_48h	None	Human	SUM159xenograft_mouse2_2mpktrametinib30mpkIBET151_48h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194339	GSE87424	SUM159 breast carcinoma cell line: xenograft	GSM2330655	None	SUM159xenograft_mouse3_2mpktrametinib30mpkIBET151_48h	None	Human	SUM159xenograft_mouse3_2mpktrametinib30mpkIBET151_48h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194340	GSE87424	SUM159 breast carcinoma cell line: xenograft	GSM2330656	None	SUM159xenograft_mouse1_30mpkIBET151_48h	None	Human	SUM159xenograft_mouse1_30mpkIBET151_48h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194341	GSE87424	SUM159 breast carcinoma cell line: xenograft	GSM2330657	None	SUM159xenograft_mouse2_30mpkIBET151_48h	None	Human	SUM159xenograft_mouse2_30mpkIBET151_48h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194342	GSE87424	SUM159 breast carcinoma cell line: xenograft	GSM2330658	None	SUM159xenograft_mouse3_30mpkIBET151_48h	None	Human	SUM159xenograft_mouse3_30mpkIBET151_48h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194343	GSE87424	SUM159 breast carcinoma cell line: xenograft	GSM2330659	None	SUM159xenograft_mouse1_control_48h	None	Human	SUM159xenograft_mouse1_control_48h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194344	GSE87424	SUM159 breast carcinoma cell line: xenograft	GSM2330660	None	SUM159xenograft_mouse2_control_48h	None	Human	SUM159xenograft_mouse2_control_48h	Breast_Invasive_Carcinoma_female
GSE87424	28108460	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated byPharmacologic Targeting of the P-TEFb Complex.	Gary L. Johnson Lab	SRX2194345	GSE87424	SUM159 breast carcinoma cell line: xenograft	GSM2330661	None	SUM159xenograft_mouse3_control_48h	None	Human	SUM159xenograft_mouse3_control_48h	Breast_Invasive_Carcinoma_female
